Xundou I. Li
Chinese Academy Of Medical Sciences And Peking Union Medical College, No.5 Dongdansantiao, Beijing
Beijing, 100730, China
Beijing, 100730, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Targeted drug delivery to AML by OFA/iLRP aptamer guided DNA nanostructure.
Journal: Scientific reports
Published: June 06, 2025
Early urinary candidate biomarkers and clinical outcomes of intervention in a rat model of experimental autoimmune encephalomyelitis.
Journal: Royal Society open science
Published: January 31, 2023
Novel nanotherapeutics for cancer immunotherapy by CTLA-4 aptamer-functionalized albumin nanoparticle loaded with antihistamine.
Journal: Journal of cancer research and clinical oncology
Published: January 31, 2023
Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles.
Journal: Molecules (Basel, Switzerland)
Published: January 27, 2023
Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo.
Journal: Molecules (Basel, Switzerland)
Published: February 03, 2022
Study on friction behavior at the interface between prosthetic socket and liner.
Journal: Acta of bioengineering and biomechanics
Published: November 30, 2021
Novel Complex of PD-L1 Aptamer and Holliday Junction Enhances Antitumor Efficacy in Vivo.
Journal: Molecules (Basel, Switzerland)
Published: January 06, 2021
Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel.
Journal: International journal of nanomedicine
Published: June 10, 2020
Targeted Therapy of Colon Cancer by Aptamer-Guided Holliday Junctions Loaded with Doxorubicin.
Journal: International journal of nanomedicine
Published: November 26, 2019
Selection of a novel DNA aptamer against OFA/iLRP for targeted delivery of doxorubicin to AML cells.
Selection of a novel DNA aptamer against OFA/iLRP for targeted delivery of doxorubicin to AML cells.
Journal: Scientific reports
Published: January 22, 2019
Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting.
Journal: Molecules (Basel, Switzerland)
Published: January 09, 2019
Last Updated: 09/26/2026